Incyte and Syndax Present Additional Data from Positive AGAVE-201 Trial at ASH Plenary Session Showing Axatilimab Efficacy Including Durable Responses in Chronic Graft-Versus-Host DiseaseBusiness Wire • 12/10/23
Incyte to Spotlight More Than 40 Hematology and Oncology Abstracts Including a Plenary Presentation at the ASH Annual MeetingBusiness Wire • 11/02/23
Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical ProgramsBusiness Wire • 10/31/23
Incyte Announces New Data from across its Oncology Portfolio to be Presented at ESMO Congress 2023Business Wire • 10/16/23
Knight Therapeutics Announces CMED Price Approval of Minjuvi® (tafasitamab) in BrazilGlobeNewsWire • 10/16/23
Incyte Announces New Data for Ruxolitinib Cream (Opzelura®) in Children with Atopic DermatitisBusiness Wire • 10/13/23
Data From Incyte's Povorcitinib Clinical Program to Be Featured at the 8th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA)Business Wire • 10/13/23
New Long-Term Data from Incyte Phase 3 TRuE-V Program Demonstrates Efficacy of Continued Treatment with Opzelura® (Ruxolitinib) Cream in Nonsegmental Vitiligo PatientsBusiness Wire • 10/11/23
Incyte and Mandy Moore Partner to Empower People with Atopic Dermatitis to Find Their Moments of ClarityBusiness Wire • 10/11/23
Incyte Announces Positive 52-Week Data from Phase 2b Study Evaluating Povorcitinib (INCB54707) in Patients with Extensive Nonsegmental VitiligoBusiness Wire • 10/11/23